Pan-genotype DAA for treatment of chronic hepatitis C

Abstract

Abstract: Objective To observe the therapeutic efficacy and side effects of pan-genotype DAA (sofosbuvir+velpatasvir) in the treatment of chronic hepatitis C. Methods After the informed consent was obtained from the patients, 46 cases of chronic hepatitis C that met our recruitment criteria and were inpatients or outpatients in our hospital from 2015 to 2017 were selected as the treatment group. Other 46 cases of chronic hepatitis C receiving interferon therapy were selected as the control group. The treatment group was treated with pan-genotype DAA for 12 weeks,while the control group received short-acting interferon combined with ribavirin. The therapeutic efficacy and side effects were then compared. The comparison of therapeutic efficacy ts was evaluated by Chi-square test. Results At week 12, the HCV-RNA negative rates of the treatment group and the control group were 93.47% and 50%, respectively, with the difference being statistically significant (χ²=115.565, P<0.001). The side effects of the treatment group were less than those of the control group. In the treatment group, the negative rates of HCV-RNA in gene type 1, 2, 3, 6 were 100%, 100%, 77.78%, and 100%, respectively. Conclusion In the treatment of chronic hepatitis C, pan-genotype DAA has a favorable curative effect and less side effects, with the negative conversion rates being 100% except for genotype 3. However, its therapeutic efficacy needs further prove by large scale randomized trial.

Key words: Chronic Hepatitis C, DAA, HCV-RNA, Therapeutic effects

FU Xiao-yi, JIN Xian, XU Xiao-jing, PENG Yan-zhong. Pan-genotype DAA for treatment of chronic hepatitis C[J]. Electronic Journal of Emerging Infectious Diseases, 2018, 3(1): 30-33.

References

[1] 窦晓光,魏来,任红,等.聚乙二醇干扰素在中国丙型肝炎治疗中的地位[J].中华肝脏病杂志,2015,23(9):641-643.
[2] 汪茂荣,张馨,杨志国,等.聚乙二醇干扰素α-2a联合利巴韦林治疗基因1b型慢性丙型肝炎中利巴韦林血药浓度与疗效的关系[J].中华肝脏病杂志,2016,24(3):175-180.
[3] 柯迎春,李凌华,胡凤玉,等.HIV合并HCV感染者普通干扰素治疗失败改用聚乙二醇干扰素治疗的临床观察[J].中华肝脏病杂志,2016,24(3):181-185.
[4] Jagannath M.Sherigar,et al.Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis CEur J Gastroenterol Hepatol[J]. 2017, 29(7): 767-776.
[5] 陈志伟,胡鹏,任红.值得临床关注的新挑战:丙型肝炎病毒对直接抗病毒药物的耐药[J] .中华肝脏病杂志,2016,24(3):165-169.
[6] 中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2015更新版)[J].中华肝脏病杂志,2015,23(12):906-923.
[7] 姜东旭,张翀,丁洋,等.慢性丙型肝炎与结节性甲状腺肿的相关性分析[J].中华肝脏病杂志,2015,23(3):175-179.
[8] 纪泛扑,党双锁,蔡芝芳,等.丙型肝炎失代偿期肝硬化患者的抗病毒治疗及其长期临床结局[J].中华肝脏病杂志,2015,23(9):647-652.
[9] 李展翼,刘莹,蔡庆贤,等.慢性丙型肝炎患者NS5B聚合酶抑制剂预存耐药的特点研究[J].中华肝脏病杂志,2015,23(9):653-657.
[10] 窦晓光,丁洋.我国丙型肝炎防治新策略探讨[J].传染病信息,2016,29(2):71-72,100.
[11] 世界卫生组织,全球卫生部门战略草案:病毒性肝炎,2016-2021年[EB/OL]//http://apps.who.int/gb/ebwha/pdf-files/WHA69/A69-32-ch.pdf.
[12] World Health Organization.Global health sector strategies for HIV, viral hepatits,STIs,2016-2021[EB/OL]//http://www.who.int/ hepatits/strategy2016-2021/en/.
[13] 谢尧. 中国慢性丙型肝炎抗病毒治疗DAA时代与PegIFN/RBV标准治疗[J]. 中国肝脏病杂志(电子版),2015,7(3):40-41.
[14] 李召,陈志伟,任红,等.丙型肝炎直接抗病毒治疗耐药相关突变的临床意义[J] .中华肝脏病杂志,2017,25(3):170-174.
[15] 黄睿,魏来.2014年丙型肝炎领域在研究进展[J].中华肝脏病杂志,2015,23(2):81-85.
[16] 谢青,陈新月,谢尧,等.治愈丙型肝炎正当时[J].中华肝脏病杂志,2015,23(9):644-646.
[17] 张玉,徐小元.直接抗丙肝病毒药物耐药及预存耐药的研究[J].中华医学杂志,2015,95(31):2569-2571.
[18] 陈国凤. DAAs时代丙肝治疗的问题与挑战[J].医学研究杂志,2016,45(4):1-3,7.
[19] Aschenbrenner DS.New Drug Treats All Genotypes of Chronic HCV[J].Am J Nurs, 2016, 116(10):27.
[20] Traynor K.Oral therapy approved for chronic HCV infection of all genotypes[J]. Am J Health Syst Pharm, 2016 Aug 1, 73(15):1120.
[21] AbbVie公司丙型肝炎新药显示高治愈率[J].中国感染与化疗杂志,2017,17(1):113.
[22] 王宏亮,曹爽.抗丙型肝炎病毒药物研究的新进展[J].临床药物治疗杂志,2015,13(6):1-5.
[23] 田月,赵志刚.治疗丙肝药物研发进展综述[J].药品评价,2016,13(2):44-46.
[24] 周辛波. 全球抗丙肝药物市场纵观[J].临床药物治疗杂志,2015,13(6):91.
[25] 卞丹丹,郑素军.丙型肝炎治疗的DAA时代[J].肝博士,2016,11(3):35-37.
[26] 陈词,张伦理.PR/DAA治疗丙型肝炎谨慎的乐观[J].肝博士,2016,11(6):21-22.
[27] Nehra V,Rizza SA,Temesgen Z,et al.Sofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infection[J]. Drugs Today(Barc), 2017, 53(3):177-189.
[28] Brieva T,Rivero A,Rivero-Juarez A,et al. Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection[J]. Expret Opin Drug Metab Toxicol,,2017 Apr, 13(4):483-490.
[29] Lee R,Kottilil S,et al.Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy[J]. Hepatol Int, 2017, 11(2):161-170.
[30] Greig SL.Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C.Drugs[J].2016, 76(16):1567-1578.
[31] 李强,黄玉仙,陈良.慢性丙型肝炎:从发现到治愈[J]. 中华肝脏病杂志,2016,24(9):708-712.
[32] 陈立畅,谢青.丙型肝炎抗病毒治疗的时机与获益[J].中华肝脏病杂志,2017,25(3):164-169.
[33] Zeuzem S,DeMasi R, Baldini A,et al.丙型肝炎患者接受telaprevir联合聚乙二醇干扰素+利巴韦林三联疗法所致贫血风险因素[J].临床荟萃,2015,12(1):120-120.
[34] 杨松,成军.《丙型肝炎指南(2015年更新版)》解读之变革的HCV基因型[J].中国肝脏病杂志(电子版),2015,7(4):3-4.
[35] 万佳亮,贺星,白玫.直接抗丙肝药物联合治疗方案的研究进展[J].现代药物与临床,2014,29(4):442-446.
[36] 罗碧芬,魏来.丙型肝炎研究领域2016年新进展[J].中华肝脏病杂志,2017,25(3):175-180.
[37] 生物谷. FDA对多个丙肝药物发出黑框警告:可导致乙肝病毒被激活甚至致人死亡[J].上海医药,2016,37(19):80-80.
[38] 薛澄,周晨辰.慢性肾脏病伴丙型肝炎的治疗进展[J].国际泌尿系统杂志,2017,37(2):314-317.
[39] 张敏,苏海滨,周双男,等.直接作用抗病毒药物治疗丙型肝炎肝硬化和肝移植术后丙型肝炎复发的初步临床观察[J].传染病信息,2015,28(5):284-287.